Novartis AG
Pharmaceutical dosage forms
Last updated:
Abstract:
The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-ph- enylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.
Status:
Grant
Type:
Utility
Filling date:
26 Mar 2019
Issue date:
2 Nov 2021